SAN ANTONIO -- More than 2 years after treatment, no patient with high-risk prostate cancer had a confirmed biochemical recurrence after receiving postoperative apalutamide (Erleada) and androgen ...
Adding apalutamide to androgen deprivation therapy prolonged prostate-specific antigen progression-free survival in patients with biochemically recurrent prostate cancer in the phase 3 PRESTO trial.
A 1-year period of intensified androgen receptor blockade prolonged prostate-specific antigen progression-free survival (PSA-PFS) compared with androgen deprivation therapy (ADT) alone for patients ...
Prostate-specific membrane androgen PET/CT can help clinicians intensify or de-escalate care for men with prostate cancer who ...
In the article that accompanies this editorial, Aggarwal et al 8 found that 1 year of intensified androgen deprivation therapy (ADT) prolongs the time to next prostate-specific antigen progression (or ...
Longer time to relapse is associated with a decreased risk of dying from prostate cancer. PSA recurrence (PSAR) more than five years after radical prostatectomy for prostate cancer is associated with ...
Between 1995 and 2001, 206 men with localized but unfavorable-risk adenocarcinoma of the prostate were randomly assigned to receive RT or RT and AST, which was defined as 6 months of both a ...
ROCHESTER, Minn. — To help meet the potentially complex needs of patients after prostate cancer treatment and offer the precision and care necessary in the follow-up journey, Mayo Clinic’s Department ...
After skin cancer, prostate cancer is the most common cancer among men in the U.S., and 20% to 30% of men who beat it once will face a recurrence within five years. A new treatment, known as salvage ...
The American Society of Clinical Oncology (ASCO) has endorsed guidelines from the American Urological Association (AUA)/American Society for Radiation Oncology (ASTRO) on the use of adjuvant and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results